B-roll available: Video shot today showing the freezers where Cedars-Sinai will store COVID-19 vaccines. Please note: There are NO vaccines in the video. The vaccines will not arrive until next month.
A new poll of adults ages 50 to 80 suggests that achieving the widespread vaccination against COVID-19 needed to protect this high-risk group and end the pandemic will be an uphill climb, and require clear, transparent communication from health providers and others.
UNLV researcher Edwin Oh and colleagues have implemented wastewater surveillance programs to screen samples for the presence of COVID-19 and to extract the RNA from the SARS-COV-2 virus to find targets that make vaccines more effective.
A widely used tuberculosis vaccine is associated with reduced likelihood of contracting COVID-19 (coronavirus), according to a new study by Cedars-Sinai. The findings raise the possibility that a vaccine already approved by the U.S. Food and Drug Administration may help prevent coronavirus infections or reduce severity of the disease.
Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group
A group of vaccine experts led by Children’s Hospital of Philadelphia (CHOP) has published recommendations to ensure equitable distribution of a COVID-19 vaccine when it becomes available. The framework, published today in Heath Affairs, focuses on five principles the authors believe would strengthen the current immunization delivery system to ensure equitable access to everyone for whom vaccination is recommended.
Texas Biomedical Research Institute (Texas Biomed) in San Antonio, Texas, was awarded $1 million from the Bill & Melinda Gates Foundation to test the efficacy of human monoclonal antibodies (MAbs) for the treatment of SARS-CoV-2 infection. MAbs are human-made proteins meant to mimic human immune system antibodies. Texas Biomed Professors Luis Martinez-Sobrido, Ph.D. and Jordi B. Torrelles, Ph.D. will co-lead the project to evaluate the protective efficacy of these MAbs in small rodent models, developed at Texas Biomed, on behalf of the Coronavirus Immunotherapy Consortium (CoVIC), an international nonprofit consortium evaluating MAb therapeutics for COVID-19.
Rutgers University is a clinical trial site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s phase 3 clinical research study to evaluate the safety and efficacy of Janssen’s COVID-19 vaccine candidate.
Anthony S. Fauci, MD, will discuss COVID-19 – including the latest on potential vaccines – in a free Zoom presentation at noon Nov. 18 during Medical Center Hour at the University of Virginia School of Medicine.
A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November.
Younger parents were much less likely than older parents to say they planned to vaccinate their children and themselves against COVID-19, according to a research letter published online in medRxiv by authors at the Vanderbilt University School of Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine.
In March 2020, as the pandemic was sweeping the globe and establishing roots in Australia, the Complex Systems Centre at the University of Sydney modelled how varying rates of social distancing could affect the spread of the COVID-19 pandemic across a very diverse Australian population.
The COVID-19 Research Symposium, hosted by the Mount Sinai Clinical Intelligence Center (MSCIC), is a one-day comprehensive review of advances in research by the Mount Sinai Health System to better understand and treat the coronavirus known as COVID-19.
Half of vaccines are wasted annually because they aren’t kept cold. Michigan Tech and UMass Amherst chemical engineers have discovered a way to stabilize viruses in vaccines with proteins instead of temperature.
A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papilloma viruses (HPV) has emerged. It is based on a highly specific diagnostic test that appears to indicate cancer, and predict its course, from just a pinprick of blood.
Published: November 10, 2020 | 3:47 pm | SHARE: There may be good news on the horizon regarding a COVID-19 vaccine.Pfizer and partner BioNTech reported that their trial vaccine appears to have a 90 percent efficacy rate, meaning that test subjects who received a vaccine experienced 90 percent fewer cases of symptomatic COVID-19 than those who received a placebo.
Newborns and young infants are particularly susceptible to the flu and are six times more likely to die from the infection than older children. Currently there is no flu vaccine available for babies less than 6 months old.
ACTIV-2 will evaluate the safety and efficacy of investigational treatments for adults who have COVID-19, but do not require hospitalization. ACTIV-2 is a randomized, blinded, controlled study that tests a variety of new agents against placebo. This approach allows promising investigational agents to be added and removed over the course of the study.
In a new Science Advances study, Shresta and her colleagues at LJI report that the immune system's T cells have the power to prevent Zika infection in mice. This finding suggests that effective Zika vaccines need to activate T cells to work alongside antibodies.
Canada's National Advisory Committee on Immunization (NACI) recommends vaccinating key populations, such as people at risk of severe illness or death, those at risk of transmitting the virus and essential workers, during the initial rollout of a COVID-19 vaccine in Canada.
The state of Iowa has designated $2 million in federal CARES Act funding to support university research and development of a nanovaccine to protect against COVID-19 infections. Researchers at Iowa State University and the University of Iowa will work together on a needle-free, single-dose nanovaccine.
A Phase III clinical trial to assess if a potential vaccine is effective at preventing symptomatic COVID-19 is now open for enrollment by The University of Texas Health Science Center at Houston (UTHealth) in collaboration with Memorial Hermann-Texas Medical Center.
The University of Chicago Medical Center will be a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase 3 clinical research study, ENSEMBLE trial, to evaluate the safety and efficacy of the Janssen’s investigational COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S.
In a wide-ranging talk with UCLA Health physicians, Wednesday, Oct. 28, United States Surgeon General Jerome Adams, MD, MPH, addressed the politicization of the pandemic and the means of containing the spread of COVID-19. He also offered hope that a vaccine for the virus will be available by year’s end.
More than a dozen U.S. Immigration and Customs Enforcement (ICE) detention centers experienced large, repeated outbreaks of vaccine-preventable illnesses in the last three years, according to a new study by researchers at UC San Francisco.
Wistar scientists have designed and tested the first-of-its-kind synthetic DNA vaccine against Powassan virus (POWV), targeting portions of the virus envelope protein.
University Hospitals and Case Western Reserve University announcement that UH Cleveland Medical Center has been selected as a clinical trial site for the Phase 3 global study of an investigational vaccine against SARS-CoV-2, sponsored by AstraZeneca (LSE/STO/NYSE: AZN).
Nationalistic behaviour by governments may exclude some countries from gaining access to COVID-19 vaccines and cost the global economy up to $1.2 trillion a year in GDP, according to a new study from the not-for-profit research organisation RAND Europe.
Researchers at the Johns Hopkins Bloomberg School of Public Health and Johns Hopkins University School of Medicine have been jointly awarded a major grant from the National Cancer Institute, part of the National Institutes of Health, to set up a center for research on the human serological immune response to SARS-CoV-2, the coronavirus that causes COVID-19.
One of the proteins on the virus – located on the characteristic COVID spike – has a component called the receptor-binding domain, or RBD, which is its “Achilles heel.” That is, he said, antibodies against this part of the virus have the potential to the neutralize the virus.
As the race for a COVID-19 vaccine intensifies, health care officials are reminding the public not to forget another important vaccine this fall: the flu shot. Flu season in the U.S. technically began in September, with illnesses expected to peak in December and February, according to the Centers for Disease Control (CDC). Less than half of Americans received a flu vaccine during the 2019-2020 flu season, and a staggering 405,000 hospitalizations and 22,000 deaths were attributed to influenza.
New research from an immunology team at the University of Chicago may shed light on the challenges of developing a universal flu vaccine that would provide long-lasting and broad protection against influenza viruses.
Edward Jones-Lopez, MD, MS, a Keck Medicine of USC infectious diseases expert and investigator of one of the Operation Warp Speed vaccine clinical trials, answers the questions on everyone’s mind.